FibroScan® is the non-invasive solution for comprehensive management of liver health.
Fibroscan® provides unique and patented biomarkers, LSM by VCTE™ (Liver Stiffness Measurement) and CAP™ (Controlled Attenuation Parameter) that benefit from a worldwide clinical evidence with over 2500 peer-reviewed publications and 60+ international guidelines.
myFibroScan app is your everyday FibroScan® companion to access Interpretation Guide and FibroScan® based scores in an easy, fast and intuitive way :
The Interpretation Guide utilizes data from clinical studies to assist providers in interpreting Fibroscan® examination results.
Scores enhance Fibroscan® liver disease assessment with biological markers.
Scores are presented as educational services intended for licensed healthcare professionals. While the scores are about specific medical and healthcare issues, they are not a substitute for/or replacement of personalized medical advice and are not intended to be used as the sole basis for making individualized medical or health-related decisions.
- Agile™3+ is an aid to identify NAFLD patients with advanced fibrosis by combining VCTE™ and routine clinical parameters to reduce the need for liver biopsy. High clinical performances are demonstrated in large external validation cohorts from different geographical origins.
- Agile™4 is an aid to early identify NAFLD patients with cirrhosis by combining VCTE™ and routine clinical parameters. It can help the physicians to manage the disease to prevent liver-related complications such as hepatocellular carcinoma. High clinical performances are demonstrated in large external validation cohorts from different geographical origin.
- Fast™ is an aid to identify at risk NASH patients defined as NASH + NAS≥4 + F≥2. Good to excellent performance in cohorts from different clinical settings (NAFLD tertiary care unit, screening, bariatric surgery) and geographical origins (USA, Europe, Asia). Several publications advocate the use of Fast™.
Fibroscan® provides unique and patented biomarkers, LSM by VCTE™ (Liver Stiffness Measurement) and CAP™ (Controlled Attenuation Parameter) that benefit from a worldwide clinical evidence with over 2500 peer-reviewed publications and 60+ international guidelines.
myFibroScan app is your everyday FibroScan® companion to access Interpretation Guide and FibroScan® based scores in an easy, fast and intuitive way :
The Interpretation Guide utilizes data from clinical studies to assist providers in interpreting Fibroscan® examination results.
Scores enhance Fibroscan® liver disease assessment with biological markers.
Scores are presented as educational services intended for licensed healthcare professionals. While the scores are about specific medical and healthcare issues, they are not a substitute for/or replacement of personalized medical advice and are not intended to be used as the sole basis for making individualized medical or health-related decisions.
- Agile™3+ is an aid to identify NAFLD patients with advanced fibrosis by combining VCTE™ and routine clinical parameters to reduce the need for liver biopsy. High clinical performances are demonstrated in large external validation cohorts from different geographical origins.
- Agile™4 is an aid to early identify NAFLD patients with cirrhosis by combining VCTE™ and routine clinical parameters. It can help the physicians to manage the disease to prevent liver-related complications such as hepatocellular carcinoma. High clinical performances are demonstrated in large external validation cohorts from different geographical origin.
- Fast™ is an aid to identify at risk NASH patients defined as NASH + NAS≥4 + F≥2. Good to excellent performance in cohorts from different clinical settings (NAFLD tertiary care unit, screening, bariatric surgery) and geographical origins (USA, Europe, Asia). Several publications advocate the use of Fast™.
Show More
